- Home
- CLPR vs CUE Comparison
CLPR vs CUE Comparison
Compare CLPR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- CUE
- Stock Information
- Founded
- CLPR 2015
- CUE 2014
- Country
- CLPR United States
- CUE United States
- Employees
- CLPR N/A
- CUE N/A
- Industry
- CLPR Real Estate Investment Trusts
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- CLPR Real Estate
- CUE Health Care
- Exchange
- CLPR Nasdaq
- CUE Nasdaq
- Market Cap
- CLPR 57.8M
- CUE 58.9M
- IPO Year
- CLPR 2017
- CUE 2018
- Fundamental
- Price
- CLPR $3.80
- CUE $0.64
- Analyst Decision
- CLPR
- CUE Strong Buy
- Analyst Count
- CLPR 0
- CUE 3
- Target Price
- CLPR N/A
- CUE $3.00
- AVG Volume (30 Days)
- CLPR 74.4K
- CUE 163.7K
- Earning Date
- CLPR 05-12-2025
- CUE 05-12-2025
- Dividend Yield
- CLPR 10.00%
- CUE N/A
- EPS Growth
- CLPR N/A
- CUE N/A
- EPS
- CLPR N/A
- CUE N/A
- Revenue
- CLPR $152,413,000.00
- CUE $7,991,000.00
- Revenue This Year
- CLPR N/A
- CUE N/A
- Revenue Next Year
- CLPR N/A
- CUE $25.99
- P/E Ratio
- CLPR N/A
- CUE N/A
- Revenue Growth
- CLPR 8.63
- CUE 13.83
- 52 Week Low
- CLPR $3.38
- CUE $0.45
- 52 Week High
- CLPR $7.12
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- CLPR 44.02
- CUE 38.40
- Support Level
- CLPR $3.84
- CUE $0.61
- Resistance Level
- CLPR $4.00
- CUE $0.71
- Average True Range (ATR)
- CLPR 0.13
- CUE 0.06
- MACD
- CLPR -0.03
- CUE -0.00
- Stochastic Oscillator
- CLPR 0.00
- CUE 20.67
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.